<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">RefleXion Medical</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:102356e7-63ad-4922-973d-a792f8b7e881;id=42863</id> <rights type="text">Copyright 2019, RefleXion Medical</rights> <updated>2019-09-12T13:02:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/0zOYH7YmYNIMaW5CPlI3IA==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/0zOYH7YmYNIMaW5CPlI3IA==" /> <entry> <id>https://www.globenewswire.com/news-release/2019/09/12/1914843/0/en/RefleXion-Highlights-Novel-Approach-to-Radiotherapy-at-ASTRO-2019.html</id> <title type="text">RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019</title> <published>2019-09-12T13:02:00Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/09/12/1914843/0/en/RefleXion-Highlights-Novel-Approach-to-Radiotherapy-at-ASTRO-2019.html" /> <content type="html"><![CDATA[Biology-guided Radiotherapy May Improve Treatment for Early Stage Cancer and Expand Options for Metastatic Disease <pre>Biology-guided Radiotherapy May Improve Treatment for Early Stage Cancer and Expand Options for Metastatic Disease</pre>]]></content> <dc:identifier>1914843</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Thu, 12 Sep 2019 16:24 GMT</dc:modified> <media:content medium="image" type="image/png" width="600" url="https://ml.globenewswire.com/Resource/Download/315aad58-aef0-43c7-aa5f-fb418794c868"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2019/09/12/1914843/0/en/RefleXion-Highlights-Novel-Approach-to-Radiotherapy-at-ASTRO-2019.html"> <img src="https://ml.globenewswire.com/Resource/Download/315aad58-aef0-43c7-aa5f-fb418794c868" width="600" align="left" border="0" alt="RefleXion™ X1 Machine" title="The RefleXion X1™ Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. *The RefleXion Machine requires 510(k) clearance and is not yet commercially available in the U.S." /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Trade Show</dc:subject> <dc:keyword>New Cancer Treatment</dc:keyword> <dc:keyword>Treating Metastatic Disease</dc:keyword> <dc:keyword>RefleXion Medical</dc:keyword> <dc:keyword>RefleXion X1 Machine</dc:keyword> <dc:keyword>Cancer Research and Treatment</dc:keyword> <dc:keyword>Cancer</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/07/16/1883342/0/en/RefleXion-Names-Industry-Expert-Thorsten-Melcher-as-Chief-Business-Officer.html</id> <title type="text">RefleXion Names Industry Expert Thorsten Melcher as Chief Business Officer</title> <published>2019-07-16T13:00:00Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/07/16/1883342/0/en/RefleXion-Names-Industry-Expert-Thorsten-Melcher-as-Chief-Business-Officer.html" /> <content type="html"><![CDATA[<p align="left">HAYWARD, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=DONIID0QrqPnmivEXHyPxt8C1NPA4oQKUDrQx-mipewPJN4pUTvb26EE4KluMOmditNebiLqw48YlxjpX-tRsHfuhu319cdd92iLaT3BpUQ=" rel="nofollow" target="_blank" title=""><u>RefleXion</u><sup><u>TM</u></sup><u> Medical</u></a>, a biotargeting oncology company using each cancer’s unique biology as a means to destroy it, today announced that <a href="https://www.globenewswire.com/Tracker?data=Cu3G7FGbct7X0wHAqKgoUaL6t8o6wGYerhcrsXfq0-1yuWC-ehf_8sLa_LHsd8O5Xud3I3ozQCWC6JULYfeMUJpHJKwgC-2oy39X1ChmV_LNG9I8yhXGFLZh9PARaDGF" rel="nofollow" target="_blank" title=""><u>Thorsten Melcher, Ph.D</u></a>., has joined the executive team in the role of Chief Business Officer.<br></p>]]></content> <dc:identifier>1883342</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Tue, 16 Jul 2019 13:00 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:subject>Directors and Officers</dc:subject> <dc:keyword>#NewCBO</dc:keyword> <dc:keyword>#Additiontoexecutiveteam</dc:keyword> <dc:keyword>#RefleXionAnnouncesNewCBO</dc:keyword> <dc:keyword>#ThorstenMelcher</dc:keyword> <dc:keyword>#cancercare</dc:keyword> <dc:keyword>#cancertreatment</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/05/09/1821011/0/en/RefleXion-Achieves-Key-Milestone-with-Grand-Opening-of-Manufacturing-Facility.html</id> <title type="text">RefleXion Achieves Key Milestone with Grand Opening of Manufacturing Facility</title> <published>2019-05-09T16:00:00Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/05/09/1821011/0/en/RefleXion-Achieves-Key-Milestone-with-Grand-Opening-of-Manufacturing-Facility.html" /> <content type="html"><![CDATA[<p align="left">HAYWARD, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hDiDzFAKHUm0BS2MvC-temC335TYUxCYbP92D26Ex655RZDb9vZqAC7hfcre__eu5SjnJ8bdeaHKWqtyd4Jd8Q==" rel="nofollow" target="_blank" title=""><u>RefleXion Medical</u></a>, a biotargeting oncology company using each cancer’s unique biology as a means to destroy it, today announced the opening of its new manufacturing facility at its headquarters in Hayward, Calif.<br></p>]]></content> <dc:identifier>1821011</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Thu, 09 May 2019 15:59 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Company Announcement</dc:subject> <dc:keyword>#RefleXion</dc:keyword> <dc:keyword>#manufacturing</dc:keyword> <dc:keyword>#Hayward</dc:keyword> <dc:keyword>#BgRT</dc:keyword> <dc:keyword>#CityofHayward</dc:keyword> <dc:keyword>#RefleXionMachine</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/10/18/1623451/0/en/RefleXion-to-Unveil-New-Approach-to-Cancer-Treatment-at-ASTRO.html</id> <title type="text">RefleXion to Unveil New Approach to Cancer Treatment at ASTRO</title> <published>2018-10-18T13:00:00Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/10/18/1623451/0/en/RefleXion-to-Unveil-New-Approach-to-Cancer-Treatment-at-ASTRO.html" /> <content type="html"><![CDATA[<p align="center"><em>Biology-guided Radiotherapy May Improve Physician Confidence in Treatment of Multiple Tumors</em><br></p>]]></content> <dc:identifier>1623451</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Thu, 18 Oct 2018 18:14 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:keyword>biology guided radiation thera</dc:keyword> <dc:keyword>cancer treatment</dc:keyword> <dc:keyword>radiotherapy</dc:keyword> <dc:keyword>radiation therapy</dc:keyword> <dc:keyword>radiation toxicity</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/10/15/1621219/0/en/RefleXion-Medical-Announces-Five-Key-Hires-to-Executive-Team.html</id> <title type="text">RefleXion Medical Announces Five Key Hires to Executive Team</title> <published>2018-10-15T13:00:00Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/10/15/1621219/0/en/RefleXion-Medical-Announces-Five-Key-Hires-to-Executive-Team.html" /> <content type="html"><![CDATA[Martyn Webster joins as CFO; Sean Shirvani, MD, joins as VP of Medical Affairs; Judy Bartlett-Roberto joins as VP of Marketing; Partha Ray joins as VP of Innovation Strategy; Len Lyons joins as VP of Sales <pre>Martyn Webster joins as CFO; Sean Shirvani, MD, joins as VP of Medical Affairs; Judy Bartlett-Roberto joins as VP of Marketing; Partha Ray joins as VP of Innovation Strategy; Len Lyons joins as VP of Sales</pre>]]></content> <dc:identifier>1621219</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Mon, 15 Oct 2018 13:00 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:keyword>Executive Hires</dc:keyword> <dc:keyword>People on the move</dc:keyword> <dc:keyword>cancer treatment</dc:keyword> <dc:keyword>radiation therapy</dc:keyword> <dc:keyword>oncology</dc:keyword> <dc:keyword>biotargeting</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/04/04/1459735/0/en/RefleXion-Medical-Raises-100-Million-Series-C-to-Commercialize-Revolutionary-Cancer-Treatment.html</id> <title type="text">RefleXion Medical Raises $100 Million Series C to Commercialize Revolutionary Cancer Treatment</title> <published>2018-04-04T07:01:00Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/04/04/1459735/0/en/RefleXion-Medical-Raises-100-Million-Series-C-to-Commercialize-Revolutionary-Cancer-Treatment.html" /> <content type="html"><![CDATA[World’s Only Biology-Guided Radiation Therapy Could Help Millions More Patients Worldwide <pre>World’s Only Biology-Guided Radiation Therapy Could Help Millions More Patients Worldwide </pre>]]></content> <dc:identifier>1459735</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Wed, 04 Apr 2018 07:01 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:subject>Health</dc:subject> <dc:keyword>radiotherapy</dc:keyword> <dc:keyword>cancer treatment</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/05/08/1072703/0/en/RefleXion-Medical-Appoints-Industry-Veteran-Todd-Powell-President-and-CEO.html</id> <title type="text">RefleXion Medical Appoints Industry Veteran Todd Powell President and CEO</title> <published>2017-05-08T04:00:00Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/05/08/1072703/0/en/RefleXion-Medical-Appoints-Industry-Veteran-Todd-Powell-President-and-CEO.html" /> <content type="html"><![CDATA[<p align="left"><span class="mw_region">HAYWARD, CA</span><span>--(Marketwired - May 08, 2017) - </span>RefleXion Medical, a medical equipment company developing the first biology-guided radiotherapy (BgRT) system for targeted, personalized radiotherapy, announced today that industry veteran Todd Powell has been appointed President, CEO and a Board of Directors member. Powell spent the past 29 years developing innovative products while leading global organizations in cancer care. During a distinguished 11 year career at Elekta AB, a world leader in radiation oncology solutions, Powell held senior executive roles of increasing responsibility. Most recently, he served as Executive Vice President of Comprehensive Oncology Solutions where he led a business unit with more than $1B in revenue and 1,200 employees across North America, Europe and Asia. </p>]]></content> <dc:identifier>1072703</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Tue, 19 Sep 2017 03:34 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/07/19/1072700/0/en/RefleXion-Medical-Extends-Series-B-Financing-to-52-Million-With-Investment-From-Johnson-Johnson-Innovation-JJDC.html</id> <title type="text">RefleXion Medical Extends Series B Financing to $52 Million With Investment From Johnson & Johnson Innovation -- JJDC</title> <published>2016-07-19T12:00:00Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/07/19/1072700/0/en/RefleXion-Medical-Extends-Series-B-Financing-to-52-Million-With-Investment-From-Johnson-Johnson-Innovation-JJDC.html" /> <content type="html"><![CDATA[<p><em><p>Financing Round Highlights RefleXion's Potential Contribution to Breakthrough Combination Therapies for Oncology </p></em></p><p><span class="mw_region">HAYWARD, CA</span><span>--(Marketwired - July 19, 2016) - </span>RefleXion Medical, a medical equipment company developing the first biology-guided radiotherapy system for targeted, personalized cancer treatment, announced today that it has extended its Series B round of funding to $52 million. The full Series B financing was led by KCK Group and joined by Venrock, Pfizer Venture Investments and Sofinnova Partners, RefleXion's majority shareholder. Additionally, the company is now disclosing substantial participation by Johnson & Johnson Innovation -- JJDC Inc. (JJDC) in the financing round. In conjunction with this announcement, JJDC will obtain Board Observer status at RefleXion and will also nominate a representative from Johnson & Johnson Innovation to join the company's Scientific Advisory Board. </p>]]></content> <dc:identifier>1072700</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Tue, 19 Sep 2017 03:34 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/04/21/1072696/0/en/RefleXion-Medical-Strengthens-Management-Team-to-Bring-Biology-Guided-Radiotherapy-Into-the-Clinic.html</id> <title type="text">RefleXion Medical Strengthens Management Team to Bring Biology-Guided Radiotherapy Into the Clinic</title> <published>2016-04-21T12:00:00Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/04/21/1072696/0/en/RefleXion-Medical-Strengthens-Management-Team-to-Bring-Biology-Guided-Radiotherapy-Into-the-Clinic.html" /> <content type="html"><![CDATA[<p><em><p>Kathy O'Shaughnessy, PhD, Joins as VP Clinical, Regulatory, and Quality Assurance; Calvin Huntzinger Joins as Senior Director of Product</p></em></p><p> <span class="mw_region">HAYWARD, CA </span><span>--(Marketwired - April 21, 2016) - </span>RefleXion Medical, a medical equipment company developing the first biology-guided radiotherapy (BgRT) system for targeted, personalized cancer treatment, announced today that it has appointed Kathy O'Shaughnessy as Vice President of Clinical, Regulatory, and Quality Assurance. In addition, the company also announced that radiotherapy industry veteran, Calvin Huntzinger, has joined as Senior Director of Product.</p>]]></content> <dc:identifier>1072696</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Tue, 19 Sep 2017 03:34 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/04/14/1072692/0/en/RefleXion-Medical-Raises-46-Million-Series-B-Financing-Led-by-KCK-Group.html</id> <title type="text">RefleXion Medical Raises $46 Million Series B Financing Led by KCK Group</title> <published>2016-04-14T12:00:00Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/04/14/1072692/0/en/RefleXion-Medical-Raises-46-Million-Series-B-Financing-Led-by-KCK-Group.html" /> <content type="html"><![CDATA[<p><em><p>Financing Will Support Commercialization of the First Biology-Guided Radiotherapy System for Targeted, Personalized Cancer Treatment </p></em></p><p align="justify"> <span class="mw_region">HAYWARD, CA</span><span>--(Marketwired - April 14, 2016) - </span>RefleXion Medical, a medical equipment company developing the first biology-guided radiotherapy system for targeted, personalized cancer treatment, announced today that it has closed a $46 million Series B round of funding. The financing was led by new investor KCK Group, a family investment fund. Also participating in the round were existing investors Pfizer Venture Investments, Venrock and Sofinnova Partners, RefleXion's largest shareholder. </p>]]></content> <dc:identifier>1072692</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Tue, 19 Sep 2017 03:34 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/01/19/1072688/0/en/RefleXion-Medical-Names-Frederic-H-Moll-to-Its-Board-of-Directors.html</id> <title type="text">RefleXion Medical Names Frederic H. Moll to Its Board of Directors</title> <published>2016-01-19T18:45:27Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/01/19/1072688/0/en/RefleXion-Medical-Names-Frederic-H-Moll-to-Its-Board-of-Directors.html" /> <content type="html"><![CDATA[<p><em><p>Pioneer in Surgical Robotics and Minimally Invasive Surgery to Contribute in Moving Revolutionary Biologically-Guided Radiotherapy System Into the Clinic </p></em></p><p align="justify"> <span class="mw_region">HAYWARD, CA</span><span>--(Marketwired - January 19, 2016) - </span>RefleXion Medical, a medical equipment company developing the first biologically-guided radiation therapy system for cancer treatment, announced today that it has appointed Frederic H. Moll, M.D. to the company's Board of Directors. </p>]]></content> <dc:identifier>1072688</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Tue, 19 Sep 2017 03:34 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2015/10/19/1072685/0/en/RefleXion-Medical-Achieves-Major-Milestones-in-Development-of-Biologically-Guided-Radiotherapy.html</id> <title type="text">RefleXion Medical Achieves Major Milestones in Development of Biologically-Guided Radiotherapy</title> <published>2015-10-19T19:29:58Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2015/10/19/1072685/0/en/RefleXion-Medical-Achieves-Major-Milestones-in-Development-of-Biologically-Guided-Radiotherapy.html" /> <content type="html"><![CDATA[<p><em><p>Company Completes Proof-of-Concept Prototype System and Collaborates With the University of Texas MD Anderson Cancer Center on Treatment Planning Study</p></em></p><p><span class="mw_region">HAYWARD, CA</span><span>--(Marketwired - October 19, 2015) - </span>RefleXion Medical, a privately held medical equipment company, announced today that it has completed a proof-of-concept prototype system and will be sharing key results at the 57<sup>th</sup> Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, TX.</p>]]></content> <dc:identifier>1072685</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Tue, 19 Sep 2017 03:34 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2014/09/15/1072681/0/en/RefleXion-Medical-Awarded-1-5MM-SBIR-Phase-II-Grant-From-the-National-Cancer-Institute.html</id> <title type="text">RefleXion Medical Awarded $1.5MM SBIR Phase II Grant From the National Cancer Institute</title> <published>2014-09-15T21:02:13Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2014/09/15/1072681/0/en/RefleXion-Medical-Awarded-1-5MM-SBIR-Phase-II-Grant-From-the-National-Cancer-Institute.html" /> <content type="html"><![CDATA[<p><em><p>Major Support From National Cancer Institute to Accelerate Development of Biologically-Guided Radiotherapy System</p><p></p></em></p><p><span class="mw_region">BURLINGAME, CA</span><span>--(Marketwired - September 15, 2014) - </span>RefleXion Medical Inc. announced today that it has been awarded a $1.5MM Small Business Innovation Research (SBIR) Phase II grant from the National Cancer Institute (NCI). </p>]]></content> <dc:identifier>1072681</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Tue, 19 Sep 2017 03:34 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2014/06/10/1072678/0/en/RefleXion-Medical-Appoints-David-Q-Larkin-as-Vice-President-of-Engineering.html</id> <title type="text">RefleXion Medical Appoints David Q. Larkin as Vice President of Engineering</title> <published>2014-06-10T21:11:21Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2014/06/10/1072678/0/en/RefleXion-Medical-Appoints-David-Q-Larkin-as-Vice-President-of-Engineering.html" /> <content type="html"><![CDATA[<p><em><p>Seasoned Executive in Robotic Surgery and Medical Capital Equipment to Lead Design and Development of Company's Biologically-Guided Radiotherapy System</p></em></p><p><span class="mw_region">BURLINGAME, CA</span><span>--(Marketwired - June 10, 2014) - </span>RefleXion Medical, a medical device company developing the first biologically-guided radiation therapy system for cancer treatment, announced today that it has appointed David Q. Larkin as Vice President of Engineering. An accomplished engineering leader with over 25 years of experience in the fields of medical robotic systems, mechatronics and control systems, Larkin will be responsible for assembling and leading RefleXion's world class engineering organization and will also oversee all aspects of product design and development. </p>]]></content> <dc:identifier>1072678</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Tue, 19 Sep 2017 03:34 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2014/04/03/1072674/0/en/RefleXion-Medical-Raises-11-6-Million-Series-A-Financing-Led-by-Sofinnova-Partners.html</id> <title type="text">RefleXion Medical Raises $11.6 Million Series A Financing Led by Sofinnova Partners</title> <published>2014-04-03T21:21:06Z</published> <updated>2024-11-26T23:11:16Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2014/04/03/1072674/0/en/RefleXion-Medical-Raises-11-6-Million-Series-A-Financing-Led-by-Sofinnova-Partners.html" /> <content type="html"><![CDATA[<p><em><p></p><p> Strong Syndicate Also Includes Pfizer Venture Investments and Venrock</p><p> </p></em></p><p> <span class="mw_region">BURLINGAME, CA</span><span>--(Marketwired - April 03, 2014) - </span>RefleXion Medical, a medical device company developing the first biologically-guided radiation therapy system for cancer treatment, announced today that it has closed an $11.6 million Series A financing. The round was led by Paris-based Sofinnova Partners and was joined by Pfizer Venture Investments (PVI), and Venrock. </p>]]></content> <dc:identifier>1072674</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>RefleXion Medical</dc:contributor> <dc:modified>Tue, 19 Sep 2017 03:34 GMT</dc:modified> </entry> </feed>